Cargando…

Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding

Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatment course. The dose rounding of chemotherapies is a strategy that is commonly used in clinical practice. Nevertheless, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alwhaibi, Abdulrahman M., Alshamrani, Ali A., Alenazi, Miteb A., Altwalah, Shroog F., Alameel, Nouf N., Aljabali, Noura N., Alghamdi, Sara B., Bineid, Abdulwahab I., Alwhaibi, Monira, Al Arifi, Mohamed N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488791/
https://www.ncbi.nlm.nih.gov/pubmed/37685729
http://dx.doi.org/10.3390/jcm12175662
_version_ 1785103560243937280
author Alwhaibi, Abdulrahman M.
Alshamrani, Ali A.
Alenazi, Miteb A.
Altwalah, Shroog F.
Alameel, Nouf N.
Aljabali, Noura N.
Alghamdi, Sara B.
Bineid, Abdulwahab I.
Alwhaibi, Monira
Al Arifi, Mohamed N.
author_facet Alwhaibi, Abdulrahman M.
Alshamrani, Ali A.
Alenazi, Miteb A.
Altwalah, Shroog F.
Alameel, Nouf N.
Aljabali, Noura N.
Alghamdi, Sara B.
Bineid, Abdulwahab I.
Alwhaibi, Monira
Al Arifi, Mohamed N.
author_sort Alwhaibi, Abdulrahman M.
collection PubMed
description Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatment course. The dose rounding of chemotherapies is a strategy that is commonly used in clinical practice. Nevertheless, the frequency of developed neuropathy in vincristine first-time users and the potential association with dose rounding remains elusive. Methods: A retrospective analysis was conducted on patients administered vincristine for the first time between 2016 and 2022 using the King Saud University Medical City (KSUMC) database. Patients were stratified into pediatric and adult groups. Neuropathy frequency, its association with demographic and clinical parameters, and the Impact of dose rounding were assessed using SPSS software version 28. Results: Approximately 34.6% of patients were diagnosed with neuropathy after vincristine administration. Autonomic neuropathy was common among affected adults and pediatric patients (55.1% and 56.1%, respectively), while cranial neuropathy was more frequent in pediatric patients. Higher BSA (p = 0.038) and Scr (p = 0.044) in the pediatric group, the presence of respiratory comorbidities (p = 0.044), and the use of azole antifungals (p < 0.001) in the adult group were significantly associated with neuropathy episodes. The rounding-up of vincristine doses was significantly associated with increased neuropathy occurrence (p < 0.001), while dose rounding-down was significantly associated with a decrease in neuropathy in both groups of patients (p < 0.001). Conclusions: Our findings demonstrate that autonomic neuropathy is the most common vincristine-related neuropathy, regardless of the patient’s age. Dose rounding is a significant determinant of vincristine-induced neuropathy in both groups. Further studies are needed to evaluate the variables that exacerbate or prevent neuropathy associated with the first-time use of vincristine.
format Online
Article
Text
id pubmed-10488791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104887912023-09-09 Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding Alwhaibi, Abdulrahman M. Alshamrani, Ali A. Alenazi, Miteb A. Altwalah, Shroog F. Alameel, Nouf N. Aljabali, Noura N. Alghamdi, Sara B. Bineid, Abdulwahab I. Alwhaibi, Monira Al Arifi, Mohamed N. J Clin Med Article Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatment course. The dose rounding of chemotherapies is a strategy that is commonly used in clinical practice. Nevertheless, the frequency of developed neuropathy in vincristine first-time users and the potential association with dose rounding remains elusive. Methods: A retrospective analysis was conducted on patients administered vincristine for the first time between 2016 and 2022 using the King Saud University Medical City (KSUMC) database. Patients were stratified into pediatric and adult groups. Neuropathy frequency, its association with demographic and clinical parameters, and the Impact of dose rounding were assessed using SPSS software version 28. Results: Approximately 34.6% of patients were diagnosed with neuropathy after vincristine administration. Autonomic neuropathy was common among affected adults and pediatric patients (55.1% and 56.1%, respectively), while cranial neuropathy was more frequent in pediatric patients. Higher BSA (p = 0.038) and Scr (p = 0.044) in the pediatric group, the presence of respiratory comorbidities (p = 0.044), and the use of azole antifungals (p < 0.001) in the adult group were significantly associated with neuropathy episodes. The rounding-up of vincristine doses was significantly associated with increased neuropathy occurrence (p < 0.001), while dose rounding-down was significantly associated with a decrease in neuropathy in both groups of patients (p < 0.001). Conclusions: Our findings demonstrate that autonomic neuropathy is the most common vincristine-related neuropathy, regardless of the patient’s age. Dose rounding is a significant determinant of vincristine-induced neuropathy in both groups. Further studies are needed to evaluate the variables that exacerbate or prevent neuropathy associated with the first-time use of vincristine. MDPI 2023-08-31 /pmc/articles/PMC10488791/ /pubmed/37685729 http://dx.doi.org/10.3390/jcm12175662 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alwhaibi, Abdulrahman M.
Alshamrani, Ali A.
Alenazi, Miteb A.
Altwalah, Shroog F.
Alameel, Nouf N.
Aljabali, Noura N.
Alghamdi, Sara B.
Bineid, Abdulwahab I.
Alwhaibi, Monira
Al Arifi, Mohamed N.
Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title_full Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title_fullStr Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title_full_unstemmed Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title_short Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding
title_sort vincristine-induced neuropathy in patients diagnosed with solid and hematological malignancies: the role of dose rounding
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488791/
https://www.ncbi.nlm.nih.gov/pubmed/37685729
http://dx.doi.org/10.3390/jcm12175662
work_keys_str_mv AT alwhaibiabdulrahmanm vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alshamranialia vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alenazimiteba vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT altwalahshroogf vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alameelnoufn vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT aljabalinouran vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alghamdisarab vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT bineidabdulwahabi vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alwhaibimonira vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding
AT alarifimohamedn vincristineinducedneuropathyinpatientsdiagnosedwithsolidandhematologicalmalignanciestheroleofdoserounding